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Abstract
Background: Paragangliomas of the head and neck are highly vascular and usually clinically benign tumors arising in the
paraganglia of the autonomic nervous system. A significant number of cases (10–50%) are proven to be familial. Multiple
genes encoding subunits of the mitochondrial succinate-dehydrogenase (SDH) complex are associated with hereditary
paraganglioma: SDHB, SDHC and SDHD. Furthermore, a hereditary paraganglioma family has been identified with linkage
to the PGL2 locus on 11q13. No SDH genes are known to be located in the 11q13 region, and the exact gene defect has
not yet been identified in this family.
Methods: We have performed a RNA expression microarray study in sporadic, SDHD- and PGL2-linked head and neck
paragangliomas in order to identify potential differences in gene expression leading to tumorigenesis in these genetically
defined paraganglioma subgroups. We have focused our analysis on pathways and functional gene-groups that are known
to be associated with SDH function and paraganglioma tumorigenesis, i.e. metabolism, hypoxia, and angiogenesis related
pathways. We also evaluated gene clusters of interest on chromosome 11 (i.e. the PGL2 locus on 11q13 and the imprinted
region 11p15).
Results: We found remarkable similarity in overall gene expression profiles of SDHD -linked, PGL2-linked and sporadic
paraganglioma. The supervised analysis on pathways implicated in PGL tumor formation also did not reveal significant
differences in gene expression between these paraganglioma subgroups. Moreover, we were not able to detect
differences in gene-expression of chromosome 11 regions of interest (i.e. 11q23, 11q13, 11p15).
Conclusion: The similarity in gene-expression profiles suggests that PGL2, like SDHD, is involved in the functionality of
the SDH complex, and that tumor formation in these subgroups involves the same pathways as in SDH linked
paragangliomas. We were not able to clarify the exact identity of PGL2 on 11q13. The lack of differential gene-expression
of chromosome 11 genes might indicate that chromosome 11 loss, as demonstrated in SDHD-linked paragangliomas, is
an important feature in the formation of paragangliomas regardless of their genetic background.
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Background
Paragangliomas are tumors originating in cells of neural
crest origin in the extra-adrenal paraganglia associated
with the autonomic nervous system. Most paraganglio-
mas arise in the parasympathetic paraganglia of the head
and neck region, but they can also arise in the parasympa-
thetic paraganglia of the mediastinum or in the orthosym-
pathetic para-aortic and retroperitoneal paraganglia. They
are highly vascular and usually characterized by an indo-
lent, non-invasive growth pattern. Most cases are spo-
radic, but a significant number (10–50%) have been
shown to be familial. Mutations in 3 of the 4 genes encod-
ing subunits of succinate dehydrogenase (SDH, complex
II in the mitochondrial respiratory chain) have been
implicated in the familial forms of the disease: SDHB,
SDHC, and SDHD [1-3]. In our population, the majority
of hereditary paraganglioma cases are associated with two
founder mutations in the SDHD gene on 11q23[4]. In
addition to these SDH related cases, another hereditary
paraganglioma family has been identified with linkage to
a region on 11q13, the PGL2 locus[5]. No mitochondrial
complex II genes, including SDHA, are located in the
11q13 region, and the identity and function of the PGL2
gene are yet unknown. Mutations in SDHB, SDHC and
SDHD are also implicated in the formation of phaeochro-
mocytomas, tumors arising in cells derived from the neu-
ral crest in the adrenal medulla [6-8]. In PGL2 -linked
cases no association with phaeochromocytoma formation
has been found to date. A recent genome-wide expression
study of phaeochromocytomas identified two distinct
clusters: one containing SDH- and VHL-associated phaeo-
chromocytomas and another containing MEN2- and NF1-
associated phaeochromocytomas, while both clusters
contained sporadic cases[9]. The cluster containing VHL
and SDH associated phaeochromocytomas was character-
ized by a transcription signature of reduced oxidoreduct-
ase activity and increased angiogenesis and hypoxia[9]. In
order to gain further insight into PGL2 function and iden-
tity, we have performed a gene expression study evaluat-
ing gene expression in head and neck paragangliomas of
different genetic backgrounds: SDHD -linked, PGL2 -
linked and sporadic cases without a mutation in the
SDHB, SDHC or SDHD gene. In addition to a supervised
gene-based analysis, a supervised pathway-based analysis
was performed, evaluating differences in gene-expression
for predefined pathways and functional gene groups. We
evaluated in more detail gene groups that are known to be
associated with SDH function and paraganglioma-or
phaeochromocytoma formation, i.e. metabolism, cell
cycle, hypoxia, and angiogenesis related pathways. In
addition, we evaluated the gene sets that differentiate the
SDH/VHL – from the NF1/MEN2-associated phaeochro-
mocytoma cluster in the aforementioned phaeochromo-
cytoma gene expression study, using our dataset[9].
Finally, gene clusters located within or close to the PGL2
locus on 11q13, the SDHD locus on 11q23, and the
imprinted 11p15 region were assessed. The latter region
has previously been implicated in SDHD -linked paragan-
glioma formation[10]. The results of both gene- and path-
way- based analyses show remarkable similarity in the
gene-expression profiles of SDHD -linked, PGL2 -linked
and sporadic paragangliomas, suggesting that paragangli-
oma formation involves the same mechanisms and path-
ways in these paraganglioma subgroups.
Methods
Tumor specimens
Samples from head and neck paragangliomas were
obtained from the tissue banks of the department of
Pathology at the Leiden University Medical Center
(LUMC) (all sporadic and SDHD related cases and one
PGL2 -linked case) or the University Medical Center
(UMC) St. Radboud (all but one PGL2 -linked cases). All
specimens were handled according to the ethical guide-
lines, as described in the Code for Proper Secondary Use
of Human Tissue in the Netherlands of the Dutch Federa-
tion of Medical Scientific Societies (FEDERA). Diagnosis
of paraganglioma was confirmed by histology in all cases.
All paragangliomas were carotid body tumors arising in
the carotid bifurcation in the neck. No malignant para-
gangliomas were included in the study. Eighteen paragan-
glioma cases were selected: 7 cases with a known D92Y
founder mutation in the SDHD gene, 6 cases from the
family with significant linkage tot the PGL2 locus on
11q13, and 5 sporadic cases[5]. The latter were defined as
'sporadic' because mutation scanning of SDHB, SDHC,
and SDHD was negative, while the family histories of
these cases were negative for HN-paraganglioma or any of
the other clinical stigmata that would suggest the involve-
ment of VHL, NF1 or the RET gene.
Mutation scanning
SDHB, SDHC, and SDHD genes were scanned for the pres-
ence of mutations at the laboratory for DNA diagnostics at
the LUMC. All exonic regions of these genes were tested by
direct sequencing using the Sanger method on an ABI
3177 Genetic Analyzer, starting with the exon containing
the known Dutch founder mutations in SDHD followed
by exons that had previously been found to contain path-
ogenic mutations in SDHD, SDHB, and SDHC (in that
order) in the Dutch population[4,11]. If that remained
negative, scanning was completed by analyzing the
remainder of exons of these genes. More recently, the spo-
radic, mutation-negative cases were also examined by
MLPA for the presence of large deletions in SDHB, SDHC,
and SDHD[12]. MLPA was carried out with the P226
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MLPA kit, containing probes for all exons and the pro-
moter of each of these genes (27 different probes), accord-
ing to the MRC Holland protocol[13].
RNA isolation and microarray hybridization
Tissue samples were snap frozen in liquid nitrogen and
stored at -70°C. An experienced pathologist (PCWH) esti-
mated the tumor percentage of the samples. Only samples
with a tumor percentage of more than 70% were included
in the study. Sample preparation was performed accord-
ing to the Affymetrix protocol (Affymetrix, Inc., Santa
Clara, CA)[14]. In brief, 30 5 μm sections were taken from
each frozen tissue sample and total RNA was extracted
using Trizol (Life Technologies, Inc., Rockville, MD), and
purified using RNeasy columns according to the manufac-
turers protocol (Qiagen, Valencia, CA). A minimum of 10
μg of total RNA was used to synthesize cDNA with the
Superscript Choice system (Life Technologies, Rockville,
MD). First strand cDNA synthesis was performed with T7-
(dT24) oligomer primer, followed by second strand syn-
thesis using T4 DNA polymerase. The resultant was puri-
fied using Phase Lock Gel and precipitated in ethanol.
Synthesis of biotine labeled cRNA was performed using
the BioArray HighYield Transcript Labeling Kit (Enzo
Diagnostics, Inc., Farmingdale, NY) according to the pro-
tocol of the manufacturer. In vitro transcription (IVT)
reactions took place at 37°C for 4,5 hours. The labeled
cRNA was purified using RNeasy columns (Qiagen, Valen-
cia, CA) and fragmented in fragmentation buffer at 94°C
for 35 minutes. Fragmented cRNA prepared from each
individual sample was then transferred to a specialized
Affymetrix hybridization centre (Leiden Genome Tech-
nology Centre, LGTC). Here the samples were hybridized
according to the manufacturers protocol in a concentra-
tion of 0,5 μg/μl to a human GeneChip U95A-v2 (Affyme-
trix), containing approximately 8500 probe sets. The data
discussed in this publication have been deposited in
NCBIs Gene Expression Omnibus (GEO), and are accessi-
ble through GEO Series accession number GSE12921[15].
Sample size calculation
Sample size calculations were performed according to the
method described by Pounds and Cheng[16].
Normalization and expression analysis
Acquisition and quantification of array images was per-
formed using the MAS software package (Affymetrix). All
arrays were normalized with gcrma normalization using
the R statistical software package available from Biocon-
ductor [17-19].
Unsupervised clustering analysis
Unsupervised two-way hierarchical clustering was per-
formed with complete linkage and Euclidian distance
metrics, using the R statistical software package available
from Bioconductor[18,19].
Supervised analysis
The R package 'Linear Models for Microarray Data'
(LIMMA) was used for the assessment of differential
expression of individual genes between paraganglioma
subgroups[20]. Overall gene-expression differences
between paraganglioma subgroups were evaluated with
the 'global test' designed by J.J. Goeman using the R pack-
age 'global test' available on Bioconductor[18,19,21]. In
order to evaluate subtle differences between paragangli-
oma subgroups, we analyzed all pathways in the Catalog
of Human Gene Sets v2.0, containing 1687 gene sets,
available from the Broad Institute as part of their publicly
accessible Gene Set Enrichment Analysis (GSEA) software
package [22,23]. Instead of the statistical method used in
the GSEA software, we used the global test developed by
Goeman et al., because the latter tends to have more
power to detect gene sets with small effect sizes [24-26].
Specific attention was paid to the gene sets that were sig-
nificantly represented in SDH-linked phaeochromocyto-
mas in a recent gene-expression study by Dahia et al.[9].
Next, we applied the gene set that differentiated SDHD
from MEN2-associated phaeochromocytomas in the
aforementioned study to our data using the global
test[9,21]. Furthermore, we performed a pathway based
analysis using the global test on manually curated gene
sets, focusing specifically on pathways involved in proc-
esses or conditions that are known or assumed to play a
role in paraganglioma formation, i.e. proliferation, sur-
vival, apoptosis, cell cycle regulation, metabolism and
hypoxia, based on pathways described in literature and
the publicly available pathway databases KEGG and Bio-
carta [27-29]. In addition to the evaluation of functionally
related genes we also performed the global test on some
topographically related gene groups on chromosome 11,
i.e. the PGL2 minimal haplotype on 11q13, the SDHD
region on 11q23, and 11p15, an imprinted region that
has been implicated in SDHD -linked paraganglioma and
phaeochromocytoma formation[10,21]. In all, 264 man-
ually curated pathways and functionally related gene sets
were tested. All tests, both for genes and pathways, were
corrected for multiple testing based on the false discovery
rate (FDR) criterion, using the method of Benjamini and
Hochberg[30].
Results
Due to the rarity of PGL2-linked paragangliomas, sample
sizes in this study are inevitably limited. In all, 21 samples
were hybridized including 3 duplicates. Four samples (1
SDHD-linked sample, 2 PGL2-linked samples and 1
duplicate experiment) were excluded because of poor
RNA or hybridization quality, leaving 15 different tumors
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in the analysis (5 sporadic, 6 SDHD-linked and 4 PGL2-
linked samples) (Table 1).
Sample size calculation
Calculations showed that with this sample set and assum-
ing that at least 30 to 35 genes are truly differentially
expressed between subgroups with a fold change of 2.0 or
more, at least 10 differentially expressed genes would be
detected with a false discovery rate of 0.1.
Unsupervised analysis
Two-way hierarchical clustering of SDHD-linked, PGL2 -
linked and sporadic paragangliomas revealed no clear
clusters. No grouping according to genetic background
was found (fig. 1). In fact, overall gene expression was
very similar in all paraganglioma samples, with high cor-
relation coefficients for overall gene-expression between
all tumors irrespective of genetic background.
Supervised analysis
Using the LIMMA analysis, we did not find individual
genes that are significantly differentially expressed
between sporadic, SDHD and PGL2 -linked paraganglio-
mas. The global test did not reveal significant differences
in overall gene expression between paraganglioma sub-
groups. Using all 1687 functional gene sets from the Cat-
alog of Human Gene Sets incorporated in the GSEA
software, analysis with the global test revealed no signifi-
cant differences in gene expression between SDHD and
PGL2 -linked tumors, SDHD and sporadic tumors, or
PGL2 and sporadic tumors for any gene set when cor-
rected for multiple testing. In a recent phaeochromocy-
toma gene-expression study, several gene sets from the
Catalog of Human Gene Sets were found to be signifi-
cantly represented in SDH-associated phaeochromocyto-
mas[9]. These gene sets comprise microtubule activity,
oxidoreductase activity, HIF1α, angiogenesis, proteasome
degradation, electron transport chain, CCR3, collagen and
glutathione metabolism[9]. In our study, no significant
differential expression between sporadic, SDHD and
PGL2 -linked paragangliomas was found for these gene
sets. Dahia et al. also identified a gene set differentiating
SDH- from MEN2-associated phaeochromocytomas[9].
This gene set contained 400 probes, encoding 288 differ-
ent annotated genes. 212 of these 288 genes were also rep-
resented on the Affymetrix U95A chip used in this study.
No significant differential expression between sporadic,
SDHD and PGL2 -linked head and neck paragangliomas
was observed for this gene set (data not shown). Next, we
performed the global test on manually selected pathways
assumed to play a role in paraganglioma formation, i.e.
proliferation-, survival-, apoptosis, cell cycle regulation-,
metabolism- and hypoxia related pathways. In all, 264
pathways and functional gene sets were tested. No signif-
icant differential expression was observed for any of these
gene sets between the paraganglioma subgroups (data
partially shown in fig. 2). Last, we performed a more
detailed evaluation of genes located on chromosome 11
loci of interest (11q23, 11q13 and 11p15). This analysis
also did not reveal significant differences between para-
ganglioma subgroups (data partially shown in fig. 3).
Discussion
In our gene-expression analysis of sporadic, SDHD – and
PGL2 -linked paragangliomas of the head and neck, no
significant differences in gene-expression profile were
Table 1: Clinicopathological characteristics and mutation status
sample tumor location family history mutation sex age at onset (yrs) multiple
paragangliomas
1 PGL04 CBT PGL2 - f 28 yes
2 PGL01 CBT PGL2 - f 28 yes
3 PGL02 CBT PGL2 - m 37 yes
4 PGL19 CBT PGL2 - f 32 yes
5 PGL05 CBT SDHD D92Y m 43 yes
6 PGL06 CBT SDHD D92Y m 47 yes
7 PGL13 CBT SDHD D92Y f 29 yes
8 PGL14 CBT SDHD D92Y f 45 no
9 PGL16 CBT SDHD D92Y f 47 yes
10 PGL17 CBT SDHD D92Y f 74 no
11 PGL10 CBT SPOR - f 44 no
13 PGL12 CBT SPOR - f 49 no
14 PGL15 CBT SPOR - f 38 no
15 PGL23 CBT SPOR - f 70 no
16 PGL20 CBT SPOR - m 27 no
CBT = carotid body tumor; PGL2 = positive family history for PGL2-linked paragangliomas; SDHD = positive family history for SDHD-linked 
paragangliomas; SPOR = sporadic sample, negative family history of paraganglioma or phaeochromocytoma and no mutation in the SDHB, SDHC or 
SDHD gene; D92Y = Asp92Tyr, a Dutch founder mutation in the SDHD gene; m = male patient, f = female patient.
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Two way hierarchical clustering analysis of genetically defined paraganglioma subgroupsFigure 1
Two way hierarchical clustering analysis of genetically defined paraganglioma subgroups. Two way hierarchical 
clustering of PGL2-linked (yellow squares in the top row), SDHD-linked (blue squares in the top row), and sporadic (grey 
squares in the top row) head and neck paragangliomas. Samples are represented as columns and genes as rows. Expression lev-
els are normalized for each gene. The mean is zero, and the color scale indicates the expression of the gene relative to the 
mean. Red indicates high expression, black indicates mean expression, and green indicates low expression levels. Overall gene 
expression is very similar for all samples, no well defined sample clusters can be found.
PG
L0
4
PG
L1
2
PG
L0
6
PG
L0
5
PG
L2
0
PG
L1
5
PG
L2
3
PG
L1
9
PG
L0
2
PG
L0
1
PG
L1
7
PG
L1
0
PG
L1
6
PG
L1
4
PG
L1
3
G
en
es
BMC Medical Genomics 2009, 2:25 http://www.biomedcentral.com/1755-8794/2/25
Page 6 of 10
(page number not for citation purposes)
Heatmap of HIF1α target genesFigure 2
Heatmap of HIF1α target genes. Samples are represented as columns and genes as rows. Samples are ordered from left to 
right: PGL2-linked paragangliomas (yellow), SDHD-linked paragangliomas (blue), and sporadic paragangliomas (grey). In all, 264 
pathways and functional gene sets related to processes that are assumed to play a role in paraganglioma formation (i.e. prolif-
eration, survival, apoptosis, cell cycle regulation, metabolism and hypoxia) were tested (data not shown). None of them 
showed significant differential gene expression between SDHD-linked, PGL2-linked and sporadic paragangliomas, including the 
gene sets encoding SDH and HIF1α target genes involved in the processes of angiogenesis, glucose metabolism and prolifera-
tion.
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Heatmap of chromosome 11 genes located on 11p15 and the PGL2 minimal haplotype on 11q13Figure 3
Heatmap of chromosome 11 genes located on 11p15 and the PGL2 minimal haplotype on 11q13. The upper heat-
map represents genes located on chromosome 11 region 11p15, and the lower heatmap the PGL2 minimal haplotype located 
on 11q13. Samples are represented as columns and genes as rows. Samples are ordered from left to right: PGL2-linked paragan-
gliomas (yellow), SDHD-linked paragangliomas (blue), and sporadic paragangliomas (grey). No significant differences in gene 
expression can be observed for genes located on the 11p15 region, which has been implicated in SDHD-linked paraganglioma 
formation, or for genes within the PGL2 minimal haplotype located on 11q13.
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observed between these genetically defined paragangli-
oma subgroups. Instead, we found considerable similarity
between PGL2 -, SDHD – and sporadic tumor samples in
both unsupervised and supervised analyses (fig. 1, 2 and
3). This correlates well with the observation that sporadic
as well as SDHD -linked and PGL2 linked paragangliomas
of the head and neck share important clinical characteris-
tics like the age of onset of symptoms, the indolent growth
pattern, and a usually benign behaviour of the tumor,
although multiple paragangliomas are less often observed
in sporadic cases [31-34]. Furthermore, all head and neck
paraganglioma subtypes share the typical histological
architecture of the 'zellballen', groups of neoplastic chief
cells surrounded by sustentacular cells[35,36].
In a recent gene-expression study by Dahia et al. of spo-
radic, SDHB-, SDHD -, VHL-, MEN2- and NF1-associated
phaeochromocytomas, two phaeochromocytoma clusters
were identified: a cluster containing VHL-, and SDH-
linked tumors and another containing MEN2- and NF1-
linked tumors[9]. Gene set enrichment analysis showed
that microtubule activity, oxidoreductase activity, HIF1α,
angiogenesis, proteasome degeneration, electron trans-
port chain, chemokine CCR3, collagen and glutathione
metabolism gene sets were significantly represented in the
gene expression signature of SDH-linked phaeochromo-
cytomas[9]. In our study, the GSEA pathway-based super-
vised analysis of sporadic, PGL2 – and SDHD -linked
paragangliomas did not reveal significant differences
between the subgroups for all GSEA gene sets, including
the gene sets that characterized SDH tumors in the study
by Dahia et al.[9]. The authors also identified a gene set
that differentiated SDH-linked tumors from MEN2-linked
phaeochromocytomas[9]. When applying this differenti-
ating gene set to our dataset, significant differences in
gene expression could not be found. These findings sug-
gest that all paraganglioma subgroups in our study share
the characteristics that defined the SDH-linked tumors in
the study by Dahia et al., i.e. a signature of hypoxia,
reduced oxidoreductase, and increased angiogenesis[9].
Further characterization of the gene expression profiles of
head and neck paragangliomas would require compari-
son with normal paraganglionic tissue. However, due to
the microscopic size of normal paraganglia and their close
anatomical relations with essential nerves and blood ves-
sels it is not feasible to acquire this in sufficient quantity
and quality to reliably perform RNA-based tests such
gene-expression microarrays. In the present study, more
detailed analysis of manually selected pathways and func-
tional gene sets that are assumed to play a role in paragan-
glioma formation, i.e. processes of metabolism,
angiogenesis and hypoxia as well as proliferation, sur-
vival, apoptosis and cell cycle related pathways also did
not reveal significant differential expression between spo-
radic, SDHD -linked and PGL2 -linked paragangliomas. A
striking finding is that there is no significant differential
expression of SDH genes between paraganglioma sub-
groups. This is in agreement with prior observations of
SDHB suppression and enhanced expression of SDHA in
sporadic, SDHD – and PGL2 -associated tumors[9,37]. Of
further interest is the observed similar gene expression
between all paraganglioma subgroups for HIF1α and
HIF1α downstream target genes (fig. 2). HIF1α and
HIF1α downstream target genes have been shown to be
upregulated in SDH-linked tumors[9,38-40]. The mecha-
nism of HIF1α induction in tumors with SDH mutations
has recently been shown to be succinate accumulation
resulting from loss of SDH function, leading to inhibition
of HIF-α-prolyl hydroxylases and thus to elevated HIF1α
activity[39,41]. The transcription factor HIF1α regulates a
host of genes that are involved in proliferation and sur-
vival, angiogenesis and glucose metabolism, and the ele-
vated HIF1α activity or pseudo-hypoxic drive is thought
to be the basic mechanism of tumorigenesis in SDH-
linked paragangliomas[39,42,43]. It has been demon-
strated that in PGL2 – linked tumors SDH function is dis-
rupted, as it is in SDHD -linked paragangliomas[37].
PGL2 – and SDHD -linked tumors also appear to share the
features of increased HIF1α activity and upregulation of
HIF1α targets that results from SDH inactivity[9,37,41].
These findings may hold important clues for the function
of the yet unidentified PGL2 gene on 11q13, as a defect in
the yet unidentified PGL2 gene seems to have conse-
quences similar to a mutation in the SDHD gene. No
mitochondrial complex II genes are known to be located
in the 11q13 region, but the PGL2 gene could affect SDH
function by interfering with SDH assembly, transport or
insertion into the mitochondrial membrane, or encode a
cofactor that is essential for proper SDH function. Alterna-
tively, PGL2 gene function could be more directly associ-
ated with HIF1α stability and thus constitute the pseudo-
hypoxic drive that leads to paraganglioma formation. We
did not find significant differences in expression between
paraganglioma subgroups for the PGL2 minimal haplo-
type on 11q13, and further research to clarify the exact
PGL2 identity is currently ongoing.
Another important clinical feature shared by both SDHD
-and PGL2 -linked tumors is the remarkable parent-of ori-
gin dependent inheritance of disease. Inheritance of para-
ganglioma occurs in an autosomal dominant way only
when paternally transmitted, while no phenotype devel-
ops after maternal transmission[44,45]. Previously, we
demonstrated that in SDHD -linked head and neck para-
gangliomas and phaeochromocytomas this exclusive
paternal transmission of the disease is caused by consist-
ent loss of the entire maternal chromosome 11[10]. We
hypothesized that selective loss of an as yet unidentified,
imprinted gene on the 11p15 region drives this selective
chromosome loss, and may also be important in the for-
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mation of non- SDHD linked paraganglioma[10]. In line
with this hypothesis, recently H19, a paternally imprinted
gene on 11p15, has been put forward as the tumor sup-
pressor gene responsible for the parent-of-origin depend-
ent inheritance in SDHD -linked head and neck
paragangliomas[46]. In the present study, supervised
analysis of all chromosome 11 probe sets on the array, as
well as more detailed analysis of genes on chromosome
11p15, 11q23 (location of the SDHD gene) and 11q13
(location of the PGL2 locus), did not show significant
expression differences between sporadic, PGL2 – and
SDHD -linked tumors (fig. 3). It is possible that this result
reflects the loss of chromosome 11 in all these paragang-
lioma subgroups. As the relation between chromosome
loss and gene expression alterations is complex, we must
interpret the observed lack of gene expression differences
between these groups cautiously in this context. It has
been shown previously that all SDHD-linked HN-para-
gangliomas show loss of the entire copy of the wildtype
maternal chromosome 11, and the same applies to PGL2
-linked paragangliomas[10]. Partial or entire chromo-
some 11 loss has also been observed in sporadic paragan-
gliomas, although only in 2 out of 9 cases[47].
Chromosome 11 loss could thus be an important step in
paraganglioma formation irrespective of the genetic back-
ground.
Conclusion
In this study of sporadic, SDHD – and PGL2 -linked para-
gangliomas of the head and neck, we have found very sim-
ilar gene-expression profiles for all three genetic
subgroups. This correlates well with observations of com-
parable histopathology and clinical behaviour. More
detailed analysis of gene sets that have previously been
shown to characterize SDH linked tumors, as well as path-
ways known to be implicated in SDH linked paragangli-
oma formation, show no differential gene-expression for
these paraganglioma subgroups. This suggests that a
defect in the yet unidentified PGL2 gene, like a mutation
in the SDHD gene, disrupts normal SDH function. Further
gene-expression analysis of the PGL2 locus on 11q13 in
this study did not reveal the PGL2 identity. The lack of dif-
ferential gene-expression of chromosome 11 genes
between the paraganglioma subgroups might further indi-
cate that chromosome 11 loss, as demonstrated in SDHD-
linked paragangliomas, is an important feature in the for-
mation of a paraganglioma regardless of the genetic back-
ground.
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